A systematic review and meta-analysis on the association between lymphocyte subsets and the severity of COVID-19

Hojat Dehghanbanadaki1,2*, Hossein Aazami3,4*, Mahya Shabani5, Dorsa Amighi6, Farhad Seif7, Ali Zare Dehnavi8, Abdolkarim Hajighader9, Mohammad-Mehdi Mehrabi Nejad10, Mohammad Ghafoori11, Nima Hajizadeh6, Fateme Abedin5, Zahra Hajizadeh3, Mehrdad Heravi12, Parsa Panahi13,14, Ali Kabir15,16

1Metabolomics and Genomics Research Center Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
3Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
4Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
5Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
6School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
7Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
8Department of Immunology and Allergy, Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran
9Department of Radiology, Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, Iran
10School of Medicine, Iran University of Medical Sciences, Tehran, Iran
11Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
12Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran
13Metabolomics and Genomics Research Center Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
14Correspondence to Ali Kabir, MD, MPH, PhD; Email: kabir.a@iums.ac.ir, aikabir@yahoo.com

Abstract

Introduction: Prominent prognostic parameters that reflect the severity of coronavirus disease 2019 (COVID-19) to adopt an appropriate therapeutic approach are not fully identified. This systematic review and meta-analysis aimed to explore the association between lymphocyte variation and disease severity in COVID-19 individuals.

Methods: We searched Web of Science, Scopus, PubMed, EMBASE and WHO website to retrieve studies investigating lymphocyte subset counts in non-severe and severe cases of COVID-19. The pooled standardized mean difference (SMD) between two groups and the pooled average count of each lymphocyte subset were assessed by employing a random-effect model.

Results: Thirty-nine investigations on 5,087 participants, including 3,578 non-severe patients and 1,509 severe patients, were included. The pooled analysis showed that non-severe patients had higher total T lymphocytes (SMD = 1.01; 95% CI: 0.82, 1.20; P = 75.7%), T helper cells (SMD = 1.07; 95% CI: 0.85, 1.28; P = 85.4%), T cytotoxic cells (SMD = 1.07; 95% CI: 0.82, 1.32; P = 87.1%), B cells (SMD = 0.72; 95% CI: 0.45, 0.98; P = 79.2%), and natural killer cells (SMD = 0.65; 95% CI: 0.47, 0.84; P = 63.1%) than severe patients and the average count of the corresponding lymphocyte signatures in non-severe patients/severe patients were 878.88/448.40, 493.12/268.96, 311.91/158.91, 177.09/110.37, and 155.02/103.09 cells/μL, respectively.

Conclusion: Lymphopenia may be a dilemma in COVID-19 management because over-activation of lymphocytes may lead to cytokine storm or acute respiratory distress syndrome (ARDS). In contrast, lymphopenia may increase SARS-CoV-2 amplification and COVID-19 severity. Therefore, novel therapies targeting lymphocyte proliferation or contraction may counterbalance lymphocyte counts in these patients.

Introduction

In December 2019, individuals infected with a novel kind of viral pneumonia were reported in Wuhan, China. Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified to cause coronavirus disease 2019 (COVID-19) (1). The clinical manifestations of most patients with COVID-19 range from mild to severe symptoms. Lymphocyte subsets play important roles in the integrity and regulation of the immune system. Viral infections, especially SARS-CoV-2 infection, can dysregulate lymphocyte counts and function. Patients with COVID-19 showed
This meta-analysis showed reduced level of total T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells in severe cases of COVID-19 compared to non-severe cases. By considering the decrease or increase of these immune cells in patients with severe COVID-19, the appropriate diagnosis, prognosis, follow-up, targeted therapy, and response to the treatment will be more achievable in these patients.

**Key point**

This meta-analysis showed reduced level of total T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells in severe cases of COVID-19 compared to non-severe cases.

Contraindicated patterns of natural killer (NK) cells, CD4+ T cells, CD8+ T cells, and B cells (2,3). T cells play an important role in virus eradication where CD4+ T cells (T helper cells) help other immune cells, especially activated CD8+ T cells (T cytotoxic cells) produce cytokines and eliminate molecules to combat the virus. Moreover, CD4+ T cells help B cells and macrophages enhance their capacity to eliminate pathogens by antibody production and phagocytosis, respectively (3). Viral infections usually induce lymphocytosis, especially CD8+ T cell responses; however, contradictory findings have been reported regarding lymphopenia and interferonopathy in individuals with severe COVID-19; therefore, this systematic review and meta-analysis aimed to explore the association among lymphocyte variation and disease severity in COVID-19 patients.

**Methods**

**Protocol registration**

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for this systematic review and the research question was determined with PICO framework as follows: what is the alteration of lymphocyte subsets (O) in severe patients (I) compared to non-severe patients (C) with COVID-19 infection (P).

**Search strategy and study selection**

PubMed, Web of Science, Scopus, EMBASE and WHO were searched for related studies on “lymphocyte”, “severity”, and “COVID-19” from the emergence of COVID-19 to 1 April 2021. Two authors (H.D. and H.A.) independently reviewed the titles and abstracts of the retrieved articles and then all selected articles by two authors were again screened based on the full text of manuscripts. Two authors (H.D. and H.A.) had discussed the disagreements in eligibility of studies, and if they did not reach a consensus, the third author (A.K.) made a decision.

**Inclusion and exclusion criteria**

All studies investigating any lymphocyte subset including T cell, B cell, NK cell (natural killer cell), CD4+ T helper cell and CD8+ T cytotoxic cells in the severe and non-severe cases of COVID-19 were included in this study. Exclusion criteria were case reports, case series, reviews, editorials, comments, expert opinions, nonhuman studies, studies that did not report the immune signatures quantitatively, studies that did not clarify the severity status of patients, and studies on the pediatric population or patients with any medications/conditions that induced immunosuppression or changed immune cell counts.

**Data extraction**

Two authors independently extracted the following data from the included studies; authors’ name, title, country of population, study design, date of publication, total sample size, the sample size of each group, subgroup definition, number and percentage of gender, average age, and its dispersion, average lymphocyte subsets count and their dispersions. Finally, two authors compared the extraction files of each other and solved the mismatches with a third author consulted in a case of conflict.

**Quality assessment**

The risk of bias assessment of the included studies was conducted with the Newcastle-Ottawa Quality Assessment Scale (NOQAS) and conducted by two authors, independently. In this part, no disagreement was left after two authors had reviewed and discussed their files.

**Statistical analysis**

All statistical analyses were conducted in STATA software (version 14.1). First, we extracted the mean count of lymphocyte subsets and their dispersion in non-severe and severe groups of COVID-19 individuals directly or indirectly by calculating the mean and standard deviation (SD) from median and interquartile range (IQR). Second, we computed standardized mean difference (SMD) between the two groups. Finally, we carried out a meta-analysis employing the random-effects model to pool the SMDs of each lymphocyte subset. Besides, we meta-analyzed each lymphocyte subset count to determine the pooled lymphocyte subsets count in non‐severe and severe groups. We demonstrated the pooled SMDs and pooled lymphocyte subset counts in the forest plots. The Cochran Q test and I² index were applied to test the heterogeneity. P value<0.05 was considered to be significant in all statistical tests.

**Results**

**Study selection and baseline characteristics**

We retrieved a total of 5,877 documents through searching international databases. Besides, we found 15 eligible documents by manually searching the reference list of the incorporated articles. Finally, 39 articles (4-42) met the inclusion and exclusion criteria that were extracted for qualitative and quantitative analysis. Figure 1 shows the PRISMA diagram of the study. A total of 5087 participants with COVID-19 were included in our meta-analysis,
including 3578 non-severe patients and 1509 severe patients. The sample sizes of the included studies ranged from 21 to 500, with 10 to 345 in the non-severe group and 5 to 155 in the severe group. The mean age of participants ranged from 42.3 years to 65.5 years. Table 1 shows the baseline characteristics of the study population.

**Total T lymphocyte variation**
The meta-analysis on 27 studies (4-6,8-10,15,16,18-20, 22,24-27,29-32,35-39,41,42) which assessed absolute T lymphocyte count in non-severe and severe cases showed that non-severe individuals had significantly higher total T cell count than severe patients (SMD = 1.01; 95% CI: 0.82, 1.20; I² = 75.7%, P value < 0.001). Besides, we found that the average T cell count in non-severe patients was 878.88 cells/μL (95% CI: 818.08, 939.69) and in severe patients was 448.40 cells/μL (95% CI: 396.10, 500.71). The forest plots of pooled SMD for total T cell and pooled average T cell count in non-severe and severe groups are shown in Figure 2.

**CD4⁺ T cell variation**
Thirty-nine studies (4-10,12,13,15-34,37-42) explored the count of CD4⁺ T cells in non-severe and severe patients. The pooled analysis showed that non-severe patients significantly had higher CD4⁺ T cell count than severe patients (SMD = 1.07; 95% CI: 0.85, 1.28; I² = 85.4%, P value < 0.001). In this instance, non-severe patients had a pooled CD4⁺ T cell count of 268.96 cells/μL (95% CI: 239.56, 298.37). The forest plots of pooled SMD for CD4⁺ T cells and pooled average CD4⁺ T cell count in non-severe and severe groups are shown in Figure 3.

**CD8⁺ T cell variation**
Around 35 studies (4-10,12,13,15-34,37-42) explored the count of CD8⁺ T cells in non-severe and severe patients. The pooled SMD of CD8⁺ T cells between groups showed that non-severe patients significantly had higher CD8⁺ T cell count than severe patients (SMD = 1.07; 95% CI: 0.82, 1.32; I² = 87.1%, P value < 0.001). In this instance, non-severe patients had a pooled CD8⁺ T cell count of 311.91 cells/μL (95% CI: 295.70, 328.12) and severe patients had a pooled CD8⁺ T cell count of 158.91 cells/μL (95% CI: 140.05, 177.77). The forest plots of pooled SMD for CD8⁺ T cells and pooled average CD8⁺ T cell count in non-severe and severe groups are shown in Figure 4.

**B cell variation**
Twenty-two studies (4,6,9-11,13,15,16,18,19,22,24-26, 29-31,35,36,38,39,42) explored the count of B cells in non-severe and severe patients. The pooled SMD for B cells count was 0.72 with 95% CI of 0.45 to 0.98 (I² = 79.7%, P value < 0.001). Thus, the absolute B cells count was significantly higher in non-severe cases than those in severe patients. Further analysis showed that the pooled average B cells count in non-severe patients was 177.09 cells/μL (95% CI:163.06, 191.11) while in those severe
Table 1. Baseline characteristics of included studies

| Author, Year | Country | Study design | Sample size (n) | Subgroup definition | Male, n (%) | Age, mean (SD) (years) | Lymphocyte subsets |
|--------------|---------|--------------|----------------|---------------------|-------------|------------------------|--------------------|
| Chen et al (4), 2020 | China | Retrospective cross-sectional | 21 | 10 Moderate/ 11 severe | 17 (81%) | 55.9 (8) | T, NK, B, Th, Ts cells |
| Liu et al (5) 2020 | China | Retrospective cross-sectional | 110 | 49 Moderate/ 61 severe | 60 (54.5%) | 63.5 (13.8) | T, NK, Th, Ts cells |
| Xu et al (6) 2020 | China | Retrospective cross-sectional | 125 | 80 Mild/ 45 severe | 69 (55%) | 60.5 (15.1) | T, NK, B, Th, Ts cells |
| Yang et al (7) 2020 | China | Retrospective cross-sectional | 39 | 14 Moderate/ 25 severe | 11 (29%) | 57.6 (6.6) | Th, Ts cells |
| Chen et al (8) 2020 | China | Cohort (historical/retrospective) | 500 | 345 Mild, moderate/155 severe | 285 (57%) | 65 (12.7) | T, Th, Ts cells |
| Zhang et al (9) 2020 | China | Cohort (historical/retrospective) | 310 | 5 Asymptomatic/ 293 mild/ 12 severe | NR | NR | T, NK, B, Th, Ts cells |
| Qin et al (10) 2020 | China | Retrospective cross-sectional | 44 | 17 Non-severe/ 27 severe | NR | 57.1 (13.7) | T, NK, B, Th, Ts cells |
| Zheng et al (11) 2020 | China | Cohort (historical/retrospective) | 68 | 55 Mild/ 13 severe | 36 (53%) | 47.1 (48.6) | B, Th cells |
| Liu et al (12) 2020 | China | Cohort (historical/retrospective) | 76 | 46 Mild/30 severe | NR | NR | Th, Ts cells |
| Wan et al (13) 2020 | China | Cohort (prospective) | 123 | 102 Mild/ 21 severe | 66 (54%) | 46.1 (13.4) | NK, B, Th, Ts cells |
| Yang P et al (14) 2020 | China | Cohort (historical/retrospective) | 133 | 65 Mild/ 68 severe | 72 (54%) | 50.8 (15.7) | Th cells |
| Jiang et al (15) 2020 | China | Case-Control | 103 | 86 Mild, moderate/ 17 severe | 58 (56%) | 49.7 (10.5) | T, NK, B, Th, Ts cells |
| Liu et al (16) 2020 | China | Retrospective cross-sectional | 39 | 21 Mild, moderate/ 18 severe, critical | NR | 51.7 (14.4) | T, NK, B, Th, Ts cells |
| Wei et al (17) 2020 | China | Retrospective cross-sectional | 167 | 137 Non-severe/ 30 severe | 95 (57%) | 42.3 (14.9) | Th, Ts cells |
| Sun et al (18) 2020 | China | Retrospective cross-sectional | 54 | 8 Mild/ 36 moderate/ 10 severe | 31 (58%) | 47.1 (41.9) | T, NK, B, Th, Ts cells |
| He et al (19) 2020 | China | Retrospective cross-sectional | 204 | 135 Non-severe/ 69 severe | 79 (39%) | 49 (16.2) | T, NK, B, Th, Ts cells |
| Feng et al (20) 2020 | China | Retrospective cross-sectional | 240 | 214 Moderate/ 26 severe | 134 (56%) | 51.5 (18.5) | T, Th, Ts cells |
| Ma J et al (21) 2020 | China | Retrospective cross-sectional | 37 | 17 Mild/ 20 severe, critical | 20 (54%) | 64 (7) | Th, Ts cells |
| Li S et al (22) 2020 | China | Retrospective cross-sectional | 69 | 43 Non-severe/ 26 severe | 40 (58%) | 47.5 (19.3) | T, NK, B, Th, Ts cells |
| Yang F et al (23) 2020 | China | Retrospective cross-sectional | 52 | 33 Mild/ 19 severe, critical | NR | NR | Th, Ts cells |
| Li X et al (24) 2020 | China | Retrospective cross-sectional | 215 | 159 Non-severe/ 56 severe | 127 (59%) | 44.5 (23.2) | T, NK, B, Th, Ts cells |
| Han M et al (25) 2020 | China | Retrospective cross-sectional | 154 | 122 Mild/ 32 severe | 86 (56%) | 42.5 (14.7) | T, NK, B, Th, Ts cells |
| Author, Year   | Country | Study design                     | Sample size (n) | Subgroup definition | Male, n (%) | Age, mean (SD) (years) | Lymphocyte subsets |
|---------------|---------|---------------------------------|----------------|--------------------|-------------|------------------------|--------------------|
| Liu J et al (26) 2020 | China | Retrospective cross-sectional | 156           | 62 Moderate/ 94 severe | 75 (48%)    | 65.5 (13)              | T, NK, B, Th, Ts cells |
| Xiong et al (27) 2020 | China | Retrospective cross-sectional | 116           | 61 Non-severe/ 55 severe | 81 (70%)    | 58 (18.5)              | T, Th, Ts cells |
| Kalpakci et al (28) 2020 | Turkey | Retrospective cross-sectional | 40            | 20 Non-severe/ 20 severe | 20 (50%)    | 63.6 (14)              | Th, Ts cells |
| Zou et al (29) 2020 | China | Retrospective cross-sectional | 121           | 69 Non-severe/ 52 severe | 66 (55%)    | 64.4 (12.4)            | T, NK, B, Th, Ts cells |
| He et al (30) 2020 | China | Retrospective cross-sectional | 53            | 32 Mild/ 21 severe | NR         | NR                     | T, NK, B, Th, Ts cells |
| Wu et al (31) 2020 | China | Retrospective cross-sectional | 60            | 31 Mild/ 29 severe | 37 (62%)    | 57.8 (17.2)            | T, NK, B, Th, Ts cells |
| Wu et al (32) 2020 | China | Cohort (historical/retrospective) | 201          | 117 Not ARDS/ 84 ARDS | 128 (64%)   | 52.2 (11.9)            | T, Th, Ts cells |
| Chen et al (33) 2020 | China | Retrospective cross-sectional | 123           | 13 Asymptomatic/ 16 mild/ 89 moderate/ 5 severe | 65 (53%)    | 45.3 (17)              | Th, Ts cells |
| Zhou et al (34) 2020 | China | Cohort (prospective) | 83            | 66 Non-severe/ 17 severe | 42 (51%)    | 46.7 (14)              | Th, Ts cells |
| Jin et al (35) 2020 | China | Cohort (prospective) | 146           | 106 Non-severe/ 40 severe | 77 (53%)    | 46.7 (53.5)            | T, NK, B, Th, cells |
| Yi et al (36) 2020 | China | Retrospective cross-sectional | 100           | 51 Non-severe/ 49 severe | 63 (63%)    | 54.1 (15)              | T, NK, B, Th, cells |
| Xie et al (37) 2020 | China | Retrospective cross-sectional | 373           | 322 Non-severe/ 51 severe | 197 (53%)   | NR                     | T, Th, Ts cells |
| Liu et al (38) 2020 | China | Retrospective cross-sectional | 50            | 10 Mild/ 32 moderate/ 8 severe | 28 (55%)    | NR                     | T, NK, B, Th, Ts cells |
| d’Alessandro et al (39) 2020 | Italy | Retrospective cross-sectional | 54            | 40 Non-severe/ 14 severe | 33 (61%)    | 64.8 (12.2)            | T, NK, B, Th, Ts cells |
| Wang et al (40) 2020 | China | Retrospective cross-sectional | 130           | 104 Not ARDS/ 26 ARDS | 61 (47%)    | 47.1 (18.9)            | Th, Ts cells |
| Huang et al (41) 2020 | China | Cohort (prospective) | 89            | 70 Moderate/ 19 severe | NR         | NR                     | Th, Ts cells |
| Cai et al (42) 2020 | China | Cohort (prospective) | 41            | 19 Non-severe/ 22 severe | 21 (51%)    | 59.6 (13.4)            | T, NK, B, Th, Ts cells |
Figure 2. The forest plot of pooled effect on the standardized mean difference (SMD) of total T cell between non-severe and severe groups (a) and average T cell count in non-severe and severe groups (b).
Figure 3. The forest plot of pooled effect on the standardized mean difference (SMD) of CD4+ T cell between non-severe and severe groups (a) and average CD4+ T cell count in non-severe and severe groups (b).
Figure 4. The forest plot of pooled effect on the standardized mean difference (SMD) of CD8+ T cell between non-severe and severe groups (a) and average CD8+ T cell count in non-severe and severe groups (b).
patients was 110.37 cells/μL (95% CI:100.38, 120.36). The forest plots of pooled SMD for B cells and the pooled average B cell count in non-severe and severe groups are shown in Figure 5.

**Natural killer cell variation**

Twenty-two studies (4-6,9,10,13,15,16,18,19,22,24-26,29-31,35,36,38,39,42) explored the count of NK cells in non-severe and severe patients. The pooled SMD analysis showed that non-severe patients had higher NK cell counts than severe COVID-19 patients (SMD = 0.65; 95% CI: 0.47, 0.84; I² = 63.1%, P value < 0.001). In this instance, non-severe patients had pooled average NK cells count of 155.02 cells/μL (95% CI:143.46, 166.58) while severe patients had pooled average NK cells count of 103.09 cells/μL (95% CI:90.09, 116.10; Figure 6).

**Discussion**

Nowadays, researchers are extensively searching to find more robust predicting factors in COVID-19 (43). Several studies have investigated the profiles of immune cells and mediators during different phases of COVID-19 in various populations that resulted in different outcomes, possibly due to the different ethnicity, the technique of assessment, and clinical and paraclinical characteristics of the patients (2,44). Therefore, we conducted this systematic review and meta-analysis to explore the association among lymphocyte variation and disease severity because identification of lymphocyte variation may provide more accurate insight for adopting therapeutic approaches in patients with different clinical stages.

A bulk of evidence showed that although T cell counts were normal or even slightly higher in patients with mild symptoms, total T lymphocytes, CD4⁺, CD8⁺ T lymphocytes, B lymphocytes and natural killer cells were usually below the normal range in COVID-19 patients resulting in lymphopenia that was associated with disease severity and mortality in COVID-19 individuals (45,46). In the present systematic review and meta-analysis, we demonstrate that non-severe patients had a significantly higher total T cell count than severe patients. Correspondingly, the pooled analysis showed that non-severe patients had significantly higher CD4⁺ and CD8⁺ T cell, natural killer cell and B cell counts than severe patients. Although these findings are consistent with previous studies (45,46), inflammatory cytokine levels were not evaluated to correlate disease severity and cytokine storm, which might serve as a signature of severe COVID-19. A systematic meta-analysis of immune signatures in patients with COVID-19 showed that CD3⁺, CD4⁺, CD8⁺ T cells, CD4⁺CD25⁺CD127⁻ Treg cells, CD19⁺ B cells and CD16⁺CD56⁺ NK cells were significantly decreased in severe COVID-19 patients compared to non-severe ones (47). In addition, many other studies established that the total counts of lymphocyte subsets, both B and T cells, were significantly lower in both individuals with severe and non-severe COVID-19 (48,49). Several studies showed that lymphocytes were diminished in COVID-19 patients, whereas no significant difference was observed in NK cell counts (50,51). Contradictory results on NK cells necessitate further studies to shed more light on this issue. Huang et al (52), in a recent meta-analysis, demonstrated that lymphopenia correlated with poor outcomes and higher mortality in COVID-19 patients; therefore, inducing lymphocyte proliferation to increase or apoptosis to decrease (IL-7 and PD1/PD-L1 inhibitors) lymphocyte counts may help retrieve lymphocyte population in patients with severe COVID-19 for reducing COVID-19 mortality.

Most hospitalized patients have shown suboptimal, excessive, or inappropriate T cell responses in association with severe disease. Consequently, several discrete patterns of T cell responses may be found in different patients, indicating each patient is faced with different clinical outcomes. Thereby customizing therapeutic approaches may be beneficial to decrease the mortality of severe to critically ill cases with COVID-19 (53). On the other hand, a decrease of lymphocytes can be used as the prognostic factor for COVID-19 patients in the clinical setting. The lymphocytic cells cut point in our study can guide further studies to determine which patients should be warned to be a severe case of COVID-19 and cared cautiously. As antivirals, immunoglobulin, and glucocorticoids treatments have not shown a significant improvement in the survival of COVID-19 severe patients (54), immunotherapeutic strategies can be a promising treatment option for enhancing the lymphocytes. Novel therapeutic options as NK cell-based therapy, mesenchymal stem cell (MSC)-based therapy, and regulatory T cell-based therapy have been lately introduced, and trials are going on to assess these treatment strategies(55).

COVID-19 affects lymphocytes through direct and/or indirect mechanisms. The direct mechanism may be related to SARS-CoV-2 cytotoxicity, in which the virus actively replicates within infected lymphocytes (56,57). The indirect mechanism is attributed to the large production of inflammatory cytokines that potentially induce lymphocyte apoptosis (57). In addition, constitutive stimulation by a virus may cause T cell exhaustion in which T cells diminish or lose their capacity of cytokine production and effector functions (58). Similarly, SARS-CoV2-related exhaustion in lymphocytes may be due to some inhibitory cytokines, e.g., IL-10, that is significantly increased in COVID-19 patients (59). However, the exact mechanism(s) of lymphocyte reduction in individuals with severe COVID-19 remain to be completely clarified.

The present study had limitations that were common in all meta-analysis studies. We did not determine the impact of age, gender, cytokine levels, inflammatory mediators, predisposing comorbidities, effective anti-cytokine therapy...
Figure 5. The forest plot of pooled effect on the standardized mean difference (SMD) of B cell between non-severe and severe groups (a) and average B cell count in non-severe and severe groups (b).
Lymphocyte subsets in severe COVID-19

The forest plot of pooled effect on the standardized mean difference (SMD) of NK cell between non-severe and severe groups (a) and average NK cell count in non-severe and severe groups (b).

### Figure 6

| Author | Month | SMD of NK cell (95% CI) | % Weight |
|--------|-------|-------------------------|----------|
| Chen G | March | 1.50 (0.52, 2.48)       | 5.61     |
| Qin C  | March | 0.58 (0.03, 1.12)       | 3.49     |
| Wan S  | March | 2.36 (1.51, 3.22)       | 4.52     |
| Liu Z  | March | 0.78 (0.35, 1.21)       | 3.51     |
| Xu B   | April | 0.14 (0.02, 0.26)       | 5.18     |
| San Y  | April | 0.56 (0.04, 1.07)       | 0.06     |
| Sun Y  | April | 0.15 (0.02, 0.28)       | 0.02     |
| He R   | April | 0.46 (0.16, 0.76)       | 6.79     |
| Liu R  | May   | 0.27 (0.10, 0.45)       | 8.03     |
| Zhang X| May   | 0.27 (0.01, 0.53)       | 0.00     |
| Zhang X| May   | 0.08 (0.07, 0.19)       | 0.00     |
| Jiang M| May   | 0.60 (0.10, 1.10)       | 4.93     |
| Li S   | June  | 0.73 (0.26, 1.20)       | 5.10     |
| Wu Y   | July  | 0.02 (0.42, 0.14)       | 4.08     |
| Han M  | August| 0.27 (0.12, 0.42)       | 5.99     |
| Zuo L  | August| 0.75 (0.06, 1.11)       | 6.14     |
| He B   | August| 0.03 (0.35, 1.51)       | 4.05     |
| Liu F  | August| 0.81 (0.27, 1.75)       | 0.00     |
| Li P  | August| 0.19 (0.14, 0.45)       | 3.00     |
| Li X   | September| 0.71 (0.40, 1.03)   | 0.61     |
| Liu J  | October| 0.51 (0.19, 0.84)     | 6.03     |
| d’Alessandro M| October| 1.07 (0.43, 1.71) | 4.14 |
| Jin X  | November| 0.30 (0.06, 0.54)    | 5.16     |
| Colin  | November| 0.46 (0.17, 0.76)    | 4.28     |
| Yi P   | December| 0.43 (0.05, 0.82)    | 5.94     |
| Overall |        | 0.60 (0.47, 0.84)      | 100.00   |

**NOTE:** Weights are from random effects analysis.

![Forest plot](image)

### Figure 6

![Forest plot](image)
and ongoing critical trials on COVID-19 outcome; thus, further studies on severe patients, especially those who suffer from cytokine storm and ARDS (acute respiratory distress syndrome), are needed to elucidate the association between these determinants and COVID-19 severity or mortality. Furthermore, the sample population of some studies was small that may decrease the power of the studies. Finally, most of them were carried out in China, and measurements may have biased populations.

**Conclusion**

A severe type of COVID-19 may compromise the function and decrease the number of lymphocyte subsets. Thus, it is essential to identify prognostic inflammatory indicators, especially lymphocyte counts, to predict the disease severity and hospitalization. The current systematic review and meta-analysis indicated that severe COVID-19 cases had significantly lower lymphocyte counts, including CD4+ and CD8+ T cell, natural killer and B cells, than non-severe patients. COVID-19 outcome may be complicated by lymphopenia because over-activation of lymphocytes may result in cytokine storm or ARDS. On the other hand, lymphopenia may increase SARS-CoV-2 viral load and the intensity of COVID-19. Therefore, novel therapeutic strategies such as targeting lymphocyte proliferation or contraction (IL-7 and PD1/PD-L1 inhibitors, respectively) may help retrieve lymphocyte counts in patients with severe COVID-19.

**Authors’ contribution**

AK, HD, and HA were the principal investigators of the study. HD and HA were included in preparing the concept and design. HD, HA, and PP managed the analyses of the study. All authors participated in preparing the final draft of the manuscript, revised the manuscript and critically evaluated the intellectual contents. All authors have read and approved the content of the manuscript and critically evaluated the intellectual contents. All authors participated in preparing the final draft of the manuscript, revised the manuscript and critically evaluated the intellectual contents.

**Conflicts of interest**

The authors declare that they have no conflict of interests.

**Ethical issues**

Ethical issues (including plagiarism, data fabrication and double publication) were completely observed by the authors.

**Funding/Support**

None.

**Reference**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Infection and Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. doi: 10.1056/NEJMa2001017.

2. Zhou F, Yu T, Du R, Fan G, Liy J, Liu Z, et al. Clinical and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

3. McKechnie JL, Blish CA. The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19? Cell Host Microbe. 2020;27:863-9. doi: 10.1016/j.chom.2020.05.009.

4. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-9. doi: 10.1172/JCI137244.

5. Liu R, Wang Y, Li J, Han H, Xia Z, Liu F, et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clin Chim Acta. 2020;508:110-14. doi: 10.1016/j.cca.2020.05.019.

6. Xu B, Fan CY, Wang AL, ZouY I, Yu YH, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020;81:e51-60. doi: 10.1016/j.jinf.2020.04.012.

7. Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146:119-127.e4. doi: 10.1016/j.jaci.2020.04.027.

8. Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146:89-100. doi: 10.1016/j.jaci.2020.05.003.

9. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583:437-440. doi: 10.1038/s41586-020-2355-0.

10. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762-8. doi: 10.1093/cid/ciaa248.

11. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533-5. doi: 10.1038/s41423-020-0402-2.

12. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19. Viral Immunol. 2021;34:330-5. doi: 10.1089/vim.2020.0062.

13. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189:428-37. doi: 10.1111/bjh.16659.

14. Yang P, Wang P, Song Y, Zhang A, Yuan G, Cui Y. A retrospective study on the epidemiological characteristics and establishment of an early warning system of severe COVID-19 patients. J Med Virol. 2020;92:2173-80. doi: 10.1002/jmv.26022.

15. Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, et al. T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019. J Infect Dis. 2020;222:198-202. doi: 10.1093/infdis/jiaa252.

16. Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect. 2020;81:318-356. doi: 10.1016/j.jinf.2020.03.054.

17. Wei YY, Wang RR, Zhang DW, Tu YH, Chen CS, Ji S, et al. Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81:e89-e92. doi: 10.1016/j.jinf.2020.04.010.

18. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020;112:102473. doi: 10.1016/j.jaut.2020.102473.

19. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020;127:104361. doi: 10.1016/j.jcv.2020.104361.
Lymphocyte subsets in severe COVID-19

20. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020;201:1380-8. doi: 10.1164/rccm.202002-0445OC.

21. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single-center retrospective study. J Infect. 2020;81:318-56. doi: 10.1016/j.jinf.2020.04.006.

22. Li S, Jiang L, Li X, Lin F, Wang Y, Li B, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5:e138070. doi: 10.1172/jci.insight.138070.

23. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92:2067-73. doi: 10.1002/jmv.25972.

24. Li X, Liu Y, Li J, Sun L, Yang J, Xu F, et al. Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2. Immunol Res. 2020;68:398-404. doi: 10.1007/s12026-020-09156-2.

25. Han M, Xu M, Zhang Y, Liu Z, Li S, He T, et al. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med Microbiol Immunol. 2020;209(6):657-68. doi: 10.1007/s00430-020-00693-z.

26. Liu J, Liu Z, Jiang W, Wang J, Zhu M, Song J, et al. Clinical predictors of COVID-19 disease progression and death: Analysis of 214 hospitalized patients from Wuhan, China. Clin Respir J. 2021;15:293-309. doi: 10.1183/11111239.2019.

27. Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: A single-centered, retrospective, observational study. BMC Infect Dis. 2020;20:787. doi: 10.1186/s12879-020-05452-2.

28. Kalpakci Y, Hacibekiroglu T, Trak G, Karacaer C, Demirci T, Kocayigit H, et al. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+CD8+ double positive T lymphocytes as a new marker. Rev Assoc Med Bras (1992). 2020;66:1666-72. doi: 10.1590/1806-9282.6.1666.

29. Zou L, Dai L, Zhang Y, Fu W, Gao Y, Zhang Z, et al. Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients With Coronavirus Disease 2019 in Wuhan, China. Front Med (Lausanne). 2020;7:532. doi: 10.3389/fmed.2020.00352.

30. He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y, et al. The Metabolic Changes and Immune Profiles in Patients With COVID-19. Front Immunol. 2020;11:2075. doi: 10.3389/fimmu.2020.02075.

31. Wu Y, Huang X, Sun J, Xie T, Lei Y, Muhammad J, et al. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19. mSphere. 2020;5:e00362-20. doi: 10.1128/mSphere.00362-20.

32. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-943. doi: 10.1001/jama.inn.2020.0994.

33. Chen J, Han T, Huang M, Yang Y, Shang F, Zheng Y, et al. Clinical characteristics of asymptomatic carriers of novel coronavirus disease 2019: A multi-center study in Jiangsu Province. Virulence. 2020;11:1557-68. doi: 10.1080/21505594.2020.1840122.

34. Zhou YH, Li H, Qin YY, Yan XF, Lu YQ, Liu HL, et al. Predictive factors of progression to severe COVID-19. Open Med (Wars). 2020;15:805-814. doi: 10.1515/med-2020-0184.

35. Jin XH, Zhou HL, Chen LL, Wang GF, Han QY, Zhang JG, et al. Peripheral immunological features of COVID-19 patients in Taizhou, China: A retrospective study. Clin Immunol. 2021;222:108642. doi: 10.1016/j.clim.2021.108642.

36. Yi P, Yang X, Ding C, Chen Y, Xu K, Ni Q, et al. Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: A single-centre, retrospective study. BMC Infect Dis. 2020;20:943. doi: 10.1186/s12879-020-05682-4.

37. Xiel, WuQ, LinQ, LiuX, LinW, HaoS, et al. Dysfunction of adaptive immunity is related to severity of COVID-19: A retrospective study. Ther Adv Respir Dis. 2020;14:7153466620942129. doi: 10.1177/1753466620942129.

38. Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Sci Rep. 2020;10:13689. doi: 10.1038/s41598-020-70387-2.

39. d’Alessandro M, Bergantini L, Cameli P, Curatola G, Remediani L, Sestini P, et al. Peripheral biomarkers’ panel for severe COVID-19 patients. J Med Virol. 2021;93:1230-2. doi: 10.1002/jmv.26577.

40. Wang A, Gao G, Wang S, Chen M, Qian F, Fang W, et al. Clinical Characteristics and Risk Factors of Acute Respiratory Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study. Med Sci Monit. 2020;26:e925974. doi: 10.12659/MSM.925974.

41. Huang M, Wang W, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2020;8:1145. doi: 10.21037/atm.2020.5-457.

42. Cai L, Zhou X, Wang M, Mei H, Ai L, Mu S, et al. Predictive Nomogram for Severe COVID-19 and Identification of Mortality-Related Immune Features. J Allergy Clin Immunol Pract. 2021;9:177-184.e1. doi: 10.1016/j.jaip.2020.10.043.

43. Shokraee K, Mahdavi H, Panahi F, Seirafianpour F, Jahromizadeh AA, Tofghi R, et al. Accuracy of chest computed tomography and reverse transcription polymerase chain reaction in diagnosis of 2019 novel coronavirus disease; a systematic review and metaanalysis. Immunopathol Persa. 2021;7(2):e36. doi: 10.34172/ipp.2021.36.

44. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19. Front Mol Biosci. 2020;7:e138070. doi: 10.3389/fmolb.2020.00157.

45. Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864-877.e5. doi: 10.1016/j.immuni.2020.07.026.

46. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020;221:1762-9. doi: 10.1093/infdis/jiaa150.

47. Liu K, Yang T, Peng XF, Lv SM, Ye XL, Zhao TS, et al. A systematic meta-analysis of immune signatures in patients with COVID-19. Rev Med Virol. 2021;31(4):e2195. doi: 10.1002/rmv.2195.

48. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10):e137799. doi: 10.1172/jci.insight.137799.

49. Zheng Y, Huang Z, Yin G, Zhang X, Ye W, Hu Z, Hu C, et al. Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. medRxiv. 2020. doi: 10.1101/2020.02.19.20024885.

50. Li D, Long Y, Huang P, Guo W, Wu S, et al. Clinical
characteristics of 80 patients with COVID-19 in Zhuzhou City. Chin J Infect Control. 2020;19:227-33.

51. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382:1199-1207. doi: 10.1056/NEJMoa2001316.

52. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36. doi: 10.1186/s40560-020-00453-4.

53. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20:529-36. doi: 10.1038/s41577-020-0402-6.

54. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. MedRxiv. 2020. doi: 10.1101/2020.02.17.20024166.

55. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2.

56. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-432. doi: 10.1002/jmv.25685.

57. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834-847. doi: 10.1002/ajh.25829.

58. Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149-163. doi: 10.1111/imr.12823.

59. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi: 10.3389/fimmu.2020.00827.